Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

被引：2
|
作者：
Pettus, Jeremy
Vajda, Eric G.
Pipkin, James
Williamson, Gretchen
Zangmeister, Miriam A.
Li, Yong-Xi
Henry, Robert R.
D'Alessio, David
Frias, Juan P.
Zhi, Lin
Marschke, Keith
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-73-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] MK-0941, a novel glucokinase activator (GKA), lowers HbA1c in type 2 diabetes (T2DM) but lacks glycaemic durability
    Meininger, G. E.
    Shentu, Y.
    Chen, Y.
    Yu, Q.
    Sheng, D.
    Musser, B. J.
    Alba, M.
    Zhang, B. B.
    Migoya, E. M.
    Ehrhart, J.
    Kaufman, K. D.
    Goldstein, B. J.
    DIABETOLOGIA, 2010, 53 : S107 - S107
  • [32] Long-Term Clinical Outcomes Associated With LDL-C and HbA1c Goal Achievement in Patients With Type 2 Diabetes Mellitus (T2DM)
    Shi, Lizheng
    Ye, Xin
    Lu, Mei
    Wu, Eric Q.
    Sharma, Hari
    Thomason, Darren
    Fonseca, Vivian
    DIABETES, 2013, 62 : A392 - A392
  • [33] Efficacy and Tolerability of MK-0893, a Glucagon Receptor Antagonist (GRA), in Patients with Type 2 Diabetes (T2DM)
    Engel, Samuel S.
    Xu, Lei
    Andryuk, Paula J.
    Davies, Michael J.
    Amatruda, John
    Kaufman, Keith
    Goldstein, Barry J.
    DIABETES, 2011, 60 : A85 - A85
  • [34] Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%
    Merker, Ludwig
    Lund, Soren S.
    Hantel, Stefan
    Salsali, Afshin
    Kim, Gabriel
    Broedl, Uli C.
    Woerle, Hans J.
    Hach, Thomas
    DIABETES, 2014, 63 : A280 - A281
  • [35] Assessment of PF-06291874 (PF), a Glucagon Receptor Antagonist Administered as Monotherapy for Four Weeks in Patients with Type 2 Diabetes Mellitus (T2DM)
    Bergman, Arthur
    Tan, Beesan
    Somayaji, Veena
    Calle, Roberto A.
    Kazierad, David J.
    DIABETES, 2016, 65 : A283 - A283
  • [36] Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy
    Kazierad, David J.
    Chidsey, Kristin
    Somayaji, Veena R.
    Bergman, Arthur J.
    Calle, Roberto A.
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2608 - 2616
  • [37] HbA1c before and after starting treatment with metformin in a large diabetes type 2 cohort
    Vazquez-Montes, M.
    Stevens, R. J.
    Oke, J.
    Aronson, J. K.
    Farmer, A. J.
    DIABETOLOGIA, 2012, 55 : S325 - S325
  • [38] COST OF REACHING DEFINED HBA1C TARGET USING CANAGLIFLOZIN COMPARED TO DAPAGLIFLOZIN AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED ARAB EMIRATES (UAE)
    Schubert, A.
    Nielsen, A. T.
    El Khoury, A.
    Kamal, A.
    Taieb, V
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [39] EXENATIDE ONCE-WEEKLY (EQW) PHARMACOKINETICS AND HBA1C EXPOSURE RESPONSE ARE SIMILAR BETWEEN ADOLESCENT PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND ADULTS WITH T2DM.
    Edlund, H.
    Melin, J.
    Penland, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S40 - S40
  • [40] Sitagliptin Significantly Decreases the Ratio of Glycated Albumin to HbA1c in Patients with Type 2 Diabetes Mellitus
    Kurebayashi, Shogo
    Motomura, Takashi
    Goya, Kayoko
    Nakao, Makoto
    Hashimoto, Kunihiko
    Morimoto, Yasuhiko
    Kitamura, Tetsuhiro
    Fukuhara, Atsunori
    Sato, Bunzo
    Kasayama, Soji
    Shimomura, Iichiro
    Koga, Masafumi
    Otsuki, Michio
    JOURNAL OF DIABETES & METABOLISM, 2014, 5 (03)
12345